undefined

Simon Barnett

Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy

Best podcasts with Simon Barnett

Ranked by the Snipd community
undefined
Feb 9, 2024 • 45min

Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett

Gene therapy updates for rare diseases by Intellia and Ultragenyx, Novo Holdings' acquisition of Catalent for $16.5B to keep up with drug demand, NanoString bankruptcy after patent infringement lawsuit, and an interview with Simon Barnett on advancing biotech's digitization and the intersection of machine learning and biophysics in structural biology.